;PMID: 2930456
;source_file_2874.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..200] = [t:44..200]
;2)sentence:[e:201..278] = [t:201..278]
;3)section:[e:282..390] = [t:282..390]
;4)section:[e:394..490] = [t:394..490]
;5)sentence:[e:494..585] = [t:494..585]
;6)sentence:[e:586..776] = [t:586..776]
;7)sentence:[e:777..864] = [t:777..864]
;8)sentence:[e:865..1000] = [t:865..1000]
;9)sentence:[e:1001..1164] = [t:1001..1164]
;10)sentence:[e:1165..1350] = [t:1165..1350]
;11)section:[e:1354..1398] = [t:1354..1398]

;section 0 Span:0..38
;Biochem J.  1989 Jan 15;257(2):375-82.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..10] J.) (CD:[12..16] 1989)
        (NNP:[17..20] Jan) (CD:[21..23] 15) (CD:[23..27] ;257)
        (-LRB-:[27..28] -LRB-) (CD:[28..29] 2) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..34] 375) (::[34..35] -) (CD:[35..37] 82)
        (.:[37..38] .)))

;sentence 1 Span:44..200
;Purification of a growth factor related to platelet-derived growth factor and
;a  type beta transforming growth factor secreted by mouse neuroblastoma
;cells.
;[62..75]:gene-protein:"growth factor"
;[87..117]:gene-protein:"platelet-derived growth factor"
;[125..161]:gene-protein:"type beta transforming growth factor"
;[180..193]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[44..56] Purification))
      (PP (IN:[57..59] of)
        (NP
          (NP
            (NP (DT:[60..61] a)
               (NN:[62..68] growth) (NN:[69..75] factor))
            (VP (VBN:[76..83] related)
              (NP (-NONE-:[83..83] *))
              (PP-CLR (TO:[84..86] to)
                (NP
                  (ADJP (NN:[87..95] platelet) (HYPH:[95..96] -)
                        (VBN:[96..103] derived))
                  (NN:[104..110] growth) (NN:[111..117] factor)))))
          (CC:[118..121] and)
          (NP
            (NP (DT:[122..123] a)
               (NN:[125..129] type) (SYM:[130..134] beta)
               (VBG:[135..147] transforming) (NN:[148..154] growth)
               (NN:[155..161] factor))
            (VP (VBN:[162..170] secreted)
              (NP (-NONE-:[170..170] *))
              (PP (IN:[171..173] by)
                (NP-LGS (NN:[174..179] mouse) (NN:[180..193] neuroblastoma)
                        (NNS:[194..199] cells))))))))
    (.:[199..200] .)))

;sentence 2 Span:201..278
;A  general strategy for the purification of basic polypeptide growth
;factors.
;[263..277]:gene-protein:"growth factors"
(SENT
  (NP
    (NP (DT:[201..202] A) (JJ:[204..211] general) (NN:[212..220] strategy))
    (PP (IN:[221..224] for)
      (NP
        (NP (DT:[225..228] the) (NN:[229..241] purification))
        (PP (IN:[242..244] of)
          (NP (JJ:[245..250] basic)
            (NML (NN:[251..262] polypeptide)
               (NN:[263..269] growth) (NNS:[270..277] factors))))))
    (.:[277..278] .)))

;section 3 Span:282..390
;Van den Eijnden-Van Raaij AJ, Koornneef I, Van Oostwaard TM, Feyen A, Kruijer
;W,  De Laat SW, Van Zoelen EJ.
(SEC
  (FRAG (NNP:[282..285] Van) (NNP:[286..289] den) (NNP:[290..297] Eijnden)
        (HYPH:[297..298] -) (NNP:[298..301] Van) (NNP:[302..307] Raaij)
        (NNP:[308..310] AJ) (,:[310..311] ,) (NNP:[312..321] Koornneef)
        (NNP:[322..323] I) (,:[323..324] ,) (NNP:[325..328] Van)
        (NNP:[329..338] Oostwaard) (NNP:[339..341] TM) (,:[341..342] ,)
        (NNP:[343..348] Feyen) (NNP:[349..350] A) (,:[350..351] ,)
        (NNP:[352..359] Kruijer) (NNP:[360..361] W) (,:[361..362] ,)
        (NNP:[364..366] De) (NNP:[367..371] Laat) (NNP:[372..374] SW)
        (,:[374..375] ,) (NNP:[376..379] Van) (NNP:[380..386] Zoelen)
        (NNP:[387..390] EJ.)))

;section 4 Span:394..490
;Hubrecht Laboratory, Netherlands Institute for Developmental Biology,
;Utrecht,  The Netherlands.
(SEC
  (FRAG (NNP:[394..402] Hubrecht) (NNP:[403..413] Laboratory) (,:[413..414] ,)
        (NNP:[415..426] Netherlands) (NNP:[427..436] Institute)
        (IN:[437..440] for) (NNP:[441..454] Developmental)
        (NNP:[455..462] Biology) (,:[462..463] ,) (NNP:[464..471] Utrecht)
        (,:[471..472] ,) (DT:[474..477] The) (NNP:[478..489] Netherlands)
        (.:[489..490] .)))

;sentence 5 Span:494..585
;A general strategy was developed for the purification of basic polypeptide 
;growth factors.
;[570..584]:gene-protein:"growth factors"
(SENT
  (S
    (NP-SBJ-1 (DT:[494..495] A) (JJ:[496..503] general) (NN:[504..512] strategy))
    (VP (VBD:[513..516] was)
      (VP (VBN:[517..526] developed)
        (NP-1 (-NONE-:[526..526] *))
        (PP (IN:[527..530] for)
          (NP
            (NP (DT:[531..534] the) (NN:[535..547] purification))
            (PP (IN:[548..550] of)
              (NP (JJ:[551..556] basic) (NN:[557..568] polypeptide)
                 (NN:[570..576] growth) (NNS:[577..584] factors)))))))
    (.:[584..585] .)))

;sentence 6 Span:586..776
;This method is a combination of gel filtration,  weak-cation-exchange
;h.p.l.c. and reverse-phase h.p.l.c., separating the  proteins according to
;size, charge and hydrophobicity respectively.
(SENT
  (S
    (NP-SBJ (DT:[586..590] This) (NN:[591..597] method))
    (VP (VBZ:[598..600] is)
      (NP-PRD
        (NP (DT:[601..602] a) (NN:[603..614] combination))
        (PP (IN:[615..617] of)
          (NP
            (NP (NN:[618..621] gel) (NN:[622..632] filtration))
            (,:[632..633] ,)
            (NP
              (NML (JJ:[635..639] weak) (HYPH:[639..640] -)
                   (NN:[640..646] cation) (HYPH:[646..647] -)
                   (NN:[647..655] exchange))
              (NN:[656..664] h.p.l.c.))
            (CC:[665..668] and)
            (NP
              (NML (JJ:[669..676] reverse) (HYPH:[676..677] -)
                   (NN:[677..682] phase))
              (NN:[683..691] h.p.l.c.)))))
      (,:[691..692] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[692..692] *))
        (VP (VBG:[693..703] separating)
          (NP (DT:[704..707] the) (NNS:[709..717] proteins))
          (PP (VBG:[718..727] according)
            (PP (TO:[728..730] to)
              (NP (NN:[731..735] size) (,:[735..736] ,) (NN:[737..743] charge)
                  (CC:[744..747] and) (NN:[748..762] hydrophobicity))))
          (ADVP (RB:[763..775] respectively)))))
    (.:[775..776] .)))

;sentence 7 Span:777..864
;All steps  are carried out at low pH with exclusively volatile acidic buffer
;solutions.
(SENT
  (S
    (NP-SBJ-1 (DT:[777..780] All) (NNS:[781..786] steps))
    (VP (VBP:[788..791] are)
      (VP (VBN:[792..799] carried)
        (NP-1 (-NONE-:[799..799] *))
        (PRT (RP:[800..803] out))
        (PP (IN:[804..806] at)
          (NP
            (NP (JJ:[807..810] low) (NN:[811..813] pH))
            (PP (IN:[814..818] with)
              (NP
                (ADJP (RB:[819..830] exclusively) (JJ:[831..839] volatile))
                (JJ:[840..846] acidic) (NN:[847..853] buffer)
                 (NNS:[854..863] solutions)))))))
    (.:[863..864] .)))

;sentence 8 Span:865..1000
;The  sterile conditions and easy removal of salt by freeze-drying facilitate
;the  detection of the growth factors by biological assays.
;[964..978]:gene-protein:"growth factors"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[865..868] The) (JJ:[870..877] sterile)
          (NNS:[878..888] conditions))
      (CC:[889..892] and)
      (NP
        (NP (JJ:[893..897] easy) (NN:[898..905] removal))
        (PP (IN:[906..908] of)
          (NP (NN:[909..913] salt)))
        (PP (IN:[914..916] by)
          (NP (VB:[917..923] freeze) (HYPH:[923..924] -) (NN:[924..930] drying)))))
    (VP (VBP:[931..941] facilitate)
      (NP
        (NP (DT:[942..945] the) (NN:[947..956] detection))
        (PP (IN:[957..959] of)
          (NP (DT:[960..963] the)
             (NN:[964..970] growth) (NNS:[971..978] factors)))
        (PP (IN:[979..981] by)
          (NP (JJ:[982..992] biological) (NNS:[993..999] assays)))))
    (.:[999..1000] .)))

;sentence 9 Span:1001..1164
;By using this method,  homogeneous preparations of two basic growth factors
;were purified in high yield  from
;mouse-neuroblastoma-Neuro-2A-cell-conditioned medium.
;[1062..1076]:gene-protein:"growth factors"
;[1117..1130]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[1001..1003] By)
      (S-NOM
        (NP-SBJ (-NONE-:[1003..1003] *))
        (VP (VBG:[1004..1009] using)
          (NP (DT:[1010..1014] this) (NN:[1015..1021] method)))))
    (,:[1021..1022] ,)
    (NP-SBJ-1
      (NP (JJ:[1024..1035] homogeneous) (NNS:[1036..1048] preparations))
      (PP (IN:[1049..1051] of)
        (NP (CD:[1052..1055] two) (JJ:[1056..1061] basic)
           (NN:[1062..1068] growth) (NNS:[1069..1076] factors))))
    (VP (VBD:[1077..1081] were)
      (VP (VBN:[1082..1090] purified)
        (NP-1 (-NONE-:[1090..1090] *))
        (PP (IN:[1091..1093] in)
          (NP (JJ:[1094..1098] high) (NN:[1099..1104] yield)))
        (PP (IN:[1106..1110] from)
          (NP
            (NML (NN:[1111..1116] mouse) (HYPH:[1116..1117] -)
                 (NN:[1117..1130] neuroblastoma) (HYPH:[1130..1131] -)
                 (NN:[1131..1136] Neuro) (HYPH:[1136..1137] -)
                 (NN:[1137..1139] 2A) (HYPH:[1139..1140] -)
                 (NN:[1140..1144] cell) (HYPH:[1144..1145] -)
                 (VBN:[1145..1156] conditioned))
            (NN:[1157..1163] medium)))))
    (.:[1163..1164] .)))

;sentence 10 Span:1165..1350
;It is shown that  these purified factors are biochemically and
;immunologically related to  platelet-derived growth factor and type beta
;transforming growth factor from  human platelets.
;[1198..1205]:gene-protein:"factors"
;[1256..1286]:gene-protein:"platelet-derived growth factor"
;[1291..1327]:gene-protein:"type beta transforming growth factor"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[1165..1167] It))
      (SBAR-2 (-NONE-:[1167..1167] *)))
    (VP (VBZ:[1168..1170] is)
      (VP (VBN:[1171..1176] shown)
        (NP-1 (-NONE-:[1176..1176] *))
        (SBAR-2 (IN:[1177..1181] that)
          (S
            (NP-SBJ-3 (DT:[1183..1188] these) (VBN:[1189..1197] purified)
                      (NNS:[1198..1205] factors))
            (VP (VBP:[1206..1209] are)
              (ADVP (RB:[1210..1223] biochemically) (CC:[1224..1227] and)
                    (RB:[1228..1243] immunologically))
              (VP (VBN:[1244..1251] related)
                (NP-3 (-NONE-:[1251..1251] *))
                (PP-CLR (TO:[1252..1254] to)
                  (NP
                    (NP
                      (NP
                        (ADJP (NN:[1256..1264] platelet) (HYPH:[1264..1265] -)
                              (VBN:[1265..1272] derived))
                        (NN:[1273..1279] growth) (NN:[1280..1286] factor))
                      (CC:[1287..1290] and)
                      (NP
                        (NML (NN:[1291..1295] type) (SYM:[1296..1300] beta))
                        (VBG:[1301..1313] transforming) (NN:[1314..1320] growth)
                         (NN:[1321..1327] factor)))
                    (PP (IN:[1328..1332] from)
                      (NP (JJ:[1334..1339] human) (NNS:[1340..1349] platelets)))))))))))
    (.:[1349..1350] .)))

;section 11 Span:1354..1398
;PMID: 2930456 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1354..1358] PMID) (::[1358..1359] :) (CD:[1360..1367] 2930456)
        (NN:[1368..1369] -LSB-) (NNP:[1369..1375] PubMed) (::[1376..1377] -)
        (NN:[1378..1385] indexed) (IN:[1386..1389] for)
        (NNP:[1390..1398] MEDLINE-RSB-)))
